European journal of clinical pharmacology
-
Eur. J. Clin. Pharmacol. · Aug 2001
Randomized Controlled Trial Comparative Study Clinical TrialPharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly.
To compare the pharmacokinetics, pharmacodynamics, and tolerance of epoetin alfa administered subcutaneously (s.c.) once weekly (q.w.) and three times weekly (t.i.w.). ⋯ The pharmacodynamic responses were equivalent between groups despite expected differences in total erythropoietin exposure. These results indicate that the epoetin alfa 150 IU/kg t.i.w. and 40,000 IU q.w. regimens can be considered clinically equivalent.
-
Eur. J. Clin. Pharmacol. · Jan 2001
Randomized Controlled Trial Clinical TrialSalmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions.
To investigate the potential for systemic pharmacodynamic and pharmacokinetic interactions between inhaled salmeterol and fluticasone propionate when repeat doses of the two drugs are given in combination to healthy subjects. ⋯ These results in healthy subjects indicate that there is no systemic pharmacodynamic or pharmacokinetic interaction between inhaled salmeterol and fluticasone propionate when given in combination.
-
Eur. J. Clin. Pharmacol. · Nov 2000
Randomized Controlled Trial Clinical TrialEffects of metronidazole on midazolam metabolism in vitro and in vivo.
Case reports have described elevated concentrations of CYP3A4 substrates (e.g. cyclosporin) during metronidazole treatment. Therefore, we wanted to study whether metronidazole affects CYP3A4 activity, using midazolam as a model substrate in vitro and in vivo. ⋯ Metronidazole had no effects on the 1'-hydroxylation of midazolam in vitro or on the pharmacokinetics and pharmacodynamics of midazolam in vivo. These findings indicate that metronidazole is not an inhibitor of CYP3A4.
-
Eur. J. Clin. Pharmacol. · Sep 2000
Randomized Controlled Trial Multicenter Study Clinical TrialAn investigation into the efficacy of intravenous diclofenac in post-operative dental pain.
To evaluate the efficacy of single doses of intravenous diclofenac sodium (25, 50 and 75 mg) in patients with post-operative pain after third-molar surgery in a randomised, placebo-controlled study. ⋯ Single doses of i.v. diclofenac (25, 50 and 75 mg) provide significant pain relief after third-molar surgery. The efficacy of this preparation does not appear to be dose related.
-
Eur. J. Clin. Pharmacol. · Jun 2000
Randomized Controlled Trial Clinical TrialClinical efficacy, safety and pharmacokinetics of a newly developed controlled release morphine sulphate suppository in patients with cancer pain.
To compare the efficacy, safety and pharmacokinetics of a newly developed controlled-release suppository (MSR) with MS Contin tablets (MSC) in cancer patients with pain. ⋯ The newly developed controlled-release M suppository is safe and effective and may be a useful alternative for oral morphine administration in patients with cancer pain.